Advertise on podcast: Eyewire News: The Podcast

Eyewire News the Podcast reports on new products and breaking news live from thee American Academy of Ophthalmology meeting in New Orleans. Learn more about your ad choices. Visit megaphone.fm/adchoices

Eyewire News the Podcast reports on new products and breaking news live from thee American Academy of Ophthalmology meeting in New Orleans. Learn more about your ad choices. Visit megaphone.fm/adchoices

Leaders pioneering fully robotic assisted cataract surgery, discussed the technology and shared their experience treating the first human patients. Learn more about your ad choices. Visit megaphone.fm/adchoices

Kodiak Sciences meets its primary endpoint in a phase 3 trial for its DME drug candidate clearing the way for a regulatory submission; the European Commission approves Roche’s Susvimo for wet AMD; and Merck announces topline results from a pivotal phase 2b/3 trial evaluating two doses of its DME treatment candidate. Learn more about your ad choices. Visit megaphone.fm/adchoices

EyewireTV reports on new products and breaking news live from the ESCRS Congress in London. Learn more about your ad choices. Visit megaphone.fm/adchoices

EyewireTV reports on new products and breaking news live from the ESCRS Congress in London. Learn more about your ad choices. Visit megaphone.fm/adchoices

The FDA accepts a biologics license application (BLA) for a first-of-its-kind optogenetic gene therapy for RP; a software upgrade from Heru combines several pretesting assessments into a single guided workflow; and a new FDA-approved overnight orthokeratology lens is launched in the US. Learn more about your ad choices. Visit megaphone.fm/adchoices

The FDA accepts Nicox’s NDA for an investigational glaucoma drop; Bausch + Lomb provides updates on two key investigational therapies for dry eye and ocular surface pain; and Ocugen doses the first patient in a global phase 3 trial of an investigational gene therapy for geographic atrophy (GA). Learn more about your ad choices. Visit megaphone.fm/adchoices

Eyepoint Pharmaceuticals releases key phase 3 data for its wet AMD drug Duravyu; Zeiss receives FDA clearance for a cloud- and browser-based data management solution; and the FDA expands Sight Sciences’ indications for the TearCare System for the treatment of MGD. Learn more about your ad choices. Visit megaphone.fm/adchoices

Tarsus Pharmaceuticals enters into a definitive agreement to acquire Alkeus Pharmaceuticals; Harrow acquires dry eye disease nasal spray Tyrvaya from Viatris; and Italy-based Alfasigma enters into a share purchase agreement with Sever Life Sciences to acquire 100% of Nordic Pharma and its subsidiaries. Learn more about your ad choices. Visit megaphone.fm/adchoices

An interchangeable biosimilar to Eylea is launched in the US; patient enrollment is completed in two global phase 3 clinical trials evaluating Duravyu for diabetic macular edema; and Topcon receives CE mark for a fully automated ultra-widefield retinal slit scanner. Learn more about your ad choices. Visit megaphone.fm/adchoices

The CEO of Outlook Therapeutics discusses the FDA approval of wet AMD drug Lytenava; Roche receives a major boost in its efforts to commercialize wet AMD treatment Susvimo in Europe; and Glaukos reaches a milestone in its pivotal clinical study of the Preserflo MicroShunt. Learn more about your ad choices. Visit megaphone.fm/adchoices

A retinal implant system allowing patients with GA to regain some functional central vision vison is approved in Europe; Bausch + Lomb launches a new preloaded IOL delivery system in the US; and we review recent advancements and milestones in the development of novel ophthalmic treatments. Learn more about your ad choices. Visit megaphone.fm/adchoices

Tarsus acquires the maker of an investigational ocular antiseptic; Alcon and RxSight partner to jointly develop adjustable PCIOLs; and the FDA will hold a meeting to discuss Sydnexis’ investigational low-dose atropine therapy for myopia. Learn more about your ad choices. Visit megaphone.fm/adchoices

An executive from Viridian discusses the FDA approval of Lumvoa for thyroid eye disease (TED); a biosimilar referencing Lucentis is relaunched in the US; and Lumibird introduces a wireless integrated laser-indirect-ophthalmoscope. Learn more about your ad choices. Visit megaphone.fm/adchoices